约 58,900,000 个结果
在新选项卡中打开链接
  1. The New England Journal of Medicine
    https://www.nejm.org/doi/full/10.1056/NEJ…

    Tirzepatide Once Weekly for the Treatment of Obesity

    2022年6月4日 · The present trial, SURMOUNT-1, evaluated the efficacy and safety of tirzepatide in adults with obesity or overweight who did not have diabetes.

    标记:
    Tirzepatide Obesity
    Tirzepatide Once Weekly
  2. PubMed
    https://pubmed.ncbi.nlm.nih.gov/35658024

    Tirzepatide Once Weekly for the Treatment of Obesity

    标记:
    Tirzepatide Once Weekly
    Tirzepatide Weight Loss Study PubMed
    Tirzepatide Eli Lilly
  3. Eli Lilly and Company
    https://investor.lilly.com/node/51236/pdf
    [PDF]

    Tirzepatide reduced the risk of developing type 2 diabetes by …

    标记:
    Type 2 diabetes
    Burau representation
  4. Surmount 1 的研究
    PubMed
    Tirzepatide Once Weekly for the Treatment of Obesity
    Background: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. Methods: In this p...
    作者: Ania M Jastreboff
    已发布: 2022/07/21
    Keywords: Obesity is …
    PubMed
    Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis
    Aim: To assess the effect of tirzepatide on long-term risk of atherosclerotic cardiovascular disease (ASCVD) among people with obesity or overweight without diabetes from SURMOUNT-1. Materials and methods: SURMOUNT-1, a phase 3 trial, evaluated the efficacy and safety of tirzepatide in adults wi...
    作者: Emily R Hankosky
    已发布: 2024/1
    Keywords: To assess t…
    dom-pubs.onlinelibrary.wiley.com
    Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis
    Aim To assess the effect of tirzepatide on long-term risk of atherosclerotic cardiovascular disease (ASCVD) among people with obesity or overweight without diabetes from SURMOUNT-1. Materials and Methods SURMOUNT-1, a phase 3 trial, evaluated the efficacy and safety of tirzepatide in adults wit...
    作者: Emily R. Hankosk…
    已发布: 06 November 2…
    Cited By: 1
  5. Eli Lilly and Company
    https://investor.lilly.com/news-releases/news...

    Lilly's SURMOUNT-1 results published in The New England Journal …

    标记:
    Tirzepatide Obesity
    Type 2 diabetes
    Eli Lilly and Company
  6. 腾讯新闻
    https://new.qq.com/rain/a/20240821A00OJS00

    降低94%糖尿病进展风险！礼来重磅疗法长期3期试验亮眼结果公布

  8. American College of Cardiology
    https://www.acc.org/.../2022/08/04/15/32/SURMOUNT-1

    Tirzepatide Once Weekly for the Treatment of Obesity

    标记:
    Tirzepatide Obesity
    Tirzepatide Once Weekly
    American College of Cardiology
  9. Nature
    https://www.nature.com/articles/s41591-02…

    Tirzepatide after intensive lifestyle intervention in …

    2023年10月15日 · In the SURMOUNT-1 trial, patients with obesity or overweight (but not diabetes) who received tirzepatide 15 mg, with monthly brief lifestyle counseling, lost 20.9% of baseline weight at 72 weeks...

    标记:
    Tirzepatide Obesity
    Nature Medicine
  10. The Lancet
    https://www.thelancet.com/journals/lancet/…

    Tirzepatide once weekly for the treatment of obesity in …

    2023年8月19日 · The magnitude of weight reduction reached with tirzepatide in SURMOUNT-2 exceeded that shown with other approved anti-obesity medications in people with type 2 diabetes. Tirzepatide presents a promising …

    标记:
    Tirzepatide Obesity
    Type 2 diabetes
    Tirzepatide Once Weekly
  11. 腾讯新闻
    https://new.qq.com/rain/a/20220429A09S5P00

    首次实现药物减重超20％，礼来tirzepatide三期结果出炉

    标记:
    GLP1R
    Tirzepatide
  12. Eli Lilly and Company
    https://investor.lilly.com/news-releases/news...

    Lilly's tirzepatide delivered up to 22.5% weight loss in adults with ...

    标记:
    Tirzepatide Obesity
    Type 2 diabetes
    Eli Lilly and Company